Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001046

Sevoflurane

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C4H3F7O
Numéro CAS:
28523-86-6
Poids moléculaire :
200.05
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

sevoflurane

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

Clé InChI

DFEYYRMXOJXZRJ-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sevoflurane EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H315,H319

Classification des risques

Eye Irrit. 2 - Skin Irrit. 2

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

1,1,1,3,3,3-Hexafluoro-2-propanol United States Pharmacopeia (USP) Reference Standard

USP

1612594

1,1,1,3,3,3-Hexafluoro-2-propanol

USP

USP

1349003

Isoflurane

Dexmedetomidine hydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML0956

Dexmedetomidine hydrochloride

Tetramethylammonium fluoride 97%

Sigma-Aldrich

459135

Tetramethylammonium fluoride

Norifumi Kuratani et al.
Anesthesiology, 109(2), 225-232 (2008-07-24)
Sevoflurane is a popular inhalational anesthetic for general anesthesia in children. The higher incidence of emergence agitation has been suspected after sevoflurane anesthesia as compared with halothane, whereas some controlled studies showed conflicting results. In this report, the authors performed
D Schutte et al.
British journal of anaesthesia, 111(6), 967-970 (2013-07-26)
Asthma is a common disease in children and often develops early in life. This multicentre retrospective case series describe the use and effectiveness of sevoflurane inhalation therapy in a series of children with severe asthma in the paediatric intensive care
S Dahmani et al.
British journal of anaesthesia, 104(2), 216-223 (2010-01-06)
Emergence agitation (EA) in children is increased after sevoflurane anaesthesia. The efficacy of prophylactic treatment is controversial. The aim of this study was to provide a meta-analysis of the studies of the pharmacological prevention of EA in children. A comprehensive
Joachim Erb et al.
The Journal of international medical research, 42(3), 750-764 (2014-05-02)
Levosimendan is an inotropic drug with organ-protective properties due to its activation of mitochondrial K(ATP) channels. This prospective, randomized, double-blind, placebo-controlled study investigated whether administration of levosimendan prior to cardiopulmonary bypass could reduce organ dysfunction and influence subsequent secondary endpoints.
Inge K Herrmann et al.
Anesthesiology, 119(4), 901-906 (2013-07-23)
Sepsis remains a leading cause of death in intensive care units. There is growing evidence that volatile anesthetics have beneficial immunomodulatory effects on complex inflammation-mediated conditions. The authors investigated the effect of volatile anesthetics on the overall survival of mice
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique